ESMO 2019 | Urothelial carcinoma: apatorsen plus docetaxel does not provide significant value

Petros Grivas

Petros Grivas, MD, PhD, Seattle Cancer Care Alliance, Seattle, WA, discusses a trial comparing apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (NCT01780545). Dr Grivas points out that it was an important study contributing to the literature, but that the combination tested did not provide enough efficacy. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Share this video